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Abstract
The roles of serum mannan binding protein (MBP) and the mannose receptor in the cellular uptake of mannosylated
liposomes (Man-liposomes) by macrophages were studied. Man-liposomes were prepared by incorporating cholesten-5-
yloxy-N-(4-((1-imino-2-L-D-thiomannosylethyl)amino)butyl)formamide (Man-C4-Chol) into small unilamellar long circulat-
ing liposomes consisting of cholesterol (Chol) and distearoyl phosphatidylcholine (DSPC). In the in vitro cellular uptake
study with cultured mouse peritoneal macrophages, [3H]Man-liposomes were taken up to a great extent, whereas no
significant uptake was observed for [3H]cholesterol and DSPC liposomes without Man-C4-Chol (Bare-liposomes). The
uptake of [3H]Man-liposomes was dose- and temperature-dependent and inhibited by an excess of mannosylated bovine
serum albumin, suggesting their specific uptake via membrane mannose receptor-mediated endocytosis. Furthermore, it was
demonstrated that 111In-MBP binds strongly to Man-liposomes based on the recognition of Man-C4-Chol and markedly
enhanced their uptake by macrophages. These results are supported by confocal laser microscopic images. In addition, in
vivo hepatic uptake of 111In-MBP was enhanced by Man-liposomes. On the other hand, the uptake of Man-liposomes was
significantly reduced by preincubation with serum and further with MBP-depleted serum suggesting inhibitory effects of
serum proteins such as albumin on mannose receptor-mediated endocytosis. The involvement of serum-type MBP and
membrane mannose receptors in the uptake of Man-liposomes is thus suggested. ß 2001 Elsevier Science B.V. All rights
reserved.
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1. Introduction
The use of liposomes coated with ligands for re-
ceptors on cells is a promising approach for cell-spe-
ci¢c drug delivery. Among the di¡erent receptors
present on the surface of macrophages, the lectin
speci¢c for mannose residues is a promising candi-
date for liposomal targeting. Several investigators,
including us, have reported using mannose-modi¢ed
liposomes to deliver drugs, gene, antigens, and im-
munomodulators to macrophages [1^3] and demon-
strated their uptake by macrophages via mannose
receptor-mediated endocytosis. The mannose recep-
tor is a 175 kDa type I transmembrane protein and
one of the C-type lectin family containing multiple
carbohydrate recognition domains. It is expressed on
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Kup¡er cells [4], alveolar [5], peritoneal [6], and
splenic macrophages [7], monocyte-derived dendritic
cells [8], and subsets of vascular and lymphatic en-
dothelial cells [9]. Several in vivo functions have been
proposed for the mannose receptor on macrophages,
e.g. endocytosis of extracellular peroxidases and hy-
drolysis during the resolution phase of in£ammation,
phagocytosis of unopsonized pathogens [10], and
antigen capture for eventual presentation to T cells
[11].
Besides mannose receptors, mannan binding pro-
teins (MBPs) also bind to a variety of pathogens by
recognizing D-mannose, N-acetyl-D-glucosamine, or
L-fucose on their surface [12]. Serum-type MBP is
characterized as an oligomeric serum protein of he-
patic origin and belongs to the family of Ca2-de-
pendent collagenous lectins, most of which are com-
ponents of the innate immune systems of mammals
[13]. It can also activate the complement system fol-
lowing binding to its ligands in an antibody- or C1q-
independent manner (opsonin-dependent) [14].
In a series of our investigations, we have estab-
lished a novel method of introducing sugar moieties
directly into cholesterol derivatives and synthesized
cholesten-5-yloxy-N-(4-((1-imino-2-L-D-thiomannosyl-
ethyl)amino)alkyl)formamide (Man-C4-Chol) [15].
The novel mannosylated liposomes, consisting of
Man-C4-Chol, neutral distearoyl phosphatidylcho-
line (DSPC), and cholesterol(Chol) (Man-liposomes),
were rapidly eliminated from the blood circulation
and accumulate to a great extent in the liver after
intravenous administration to mice compared with
DSPC/Chol liposomes [16]. It has also been sug-
gested that uptake is mainly due to the liver non-
parenchymal cells and is signi¢cantly inhibited by
preadministration of mannosylated bovine serum al-
bumin (Man-BSA). In the present study, we describe
the hepatic uptake characteristics of Man-liposomes
in more detail. In particular, our discussion will fo-
cus on the involvement of serum MBP and the mac-
rophage membrane mannose receptor.
2. Materials and methods
2.1. Materials
DSPC and cholesteryl chloroformate were pur-
chased from Sigma Chemical (St. Louis, MO,
USA). Chol was obtained from Nacalai Tesque
(Kyoto, Japan). [3H]Cholesteryl hexadecyl ether
(CHE) was purchased from NEN Life Science Prod-
ucts (Boston, MA, USA). Indium chloride (111In)
was supplied by Nihon MedioPhysics (Takarazuka,
Japan). Man-BSA with an average degree of conju-
gation of 46 molecules per albumin molecule was
synthesized as reported previously [17]. All other
chemicals were reagent grade products obtained
commercially. Male ICR mice and ddY mice were
obtained from the Shizuoka Agriculture Coopera-
tive Association for Laboratory Animals (Shizuoka,
Japan).
2.2. Synthesis of Man-C4-Chol
Man-C4-Chol was synthesized by the method de-
scribed previously [16]. Brie£y, cholesteryl chlorofor-
mate was reacted with N-(4-aminobutyl)carbamic
acid tert-butyl ester in chloroform at room temper-
ature for 24 h and then incubated with tri£uoroacetic
acid at 4‡C for 4 h. N-(4-Aminobutyl)-(cholesten-5-
yloxy)formamide was obtained after evaporation of
the solvent. A quantity of the resultant material was
added to an excess amount of 2-imino-2-methoxyeth-
yl-1-thiomannoside [17] in pyridine containing trie-
thylamine. After 24 h at room temperature, the re-
action mixture was evaporated, resuspended in water
and dialyzed to remove any unreacted compound
and, ¢nally, lyophilized.
2.3. Preparation of liposomes
DSPC/Chol (60:40, molar ratio) and DSPC/Chol/
Man-C4-Chol (60:35:5, molar ratio) liposomes were
prepared by the method described previously [18].
Brie£y, lipids with a trace amount of [3H]CHE
were dissolved in chloroform and evaporated to dry-
ness in a round-bottomed £ask. For confocal micros-
copy, £uorescent PE-rhodamine (1 mol%) was added
to the chloroform. The dried lipid ¢lm was then vac-
uum-desiccated for at least 4 h to remove any resid-
ual organic solvent before it was hydrated in phos-
phate-bu¡ered saline (PBS, pH 7.4). The suspension
was sonicated at 65‡C for 3 min, then extruded ¢ve
times at 65‡C through 200 nm and 100 nm pore size
polycarbonate membranes. The mean vesicle diame-
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ters were determined using a laser light scattering
particle size analyzer (LS-900, Otsuka Electronics,
Osaka, Japan). The lipid compositions and mean
particle sizes are shown in Table 1.
2.4. Preparation of serum and MBP-depleted serum
Blood was obtained from the vena cava of ICR
mice under ether anesthesia and left at room tem-
perature for 1 h, then kept overnight at 4‡C. Serum
was obtained by centrifugation at 10 000Ug for
10 min at 4‡C then frozen at 320‡C until required.
MBP-depleted serum was obtained by applying the
serum twice, at a rate of 1 drop/15 s, to an a⁄nity
column of mannan Sepharose 4B that had been
equilibrated with loading bu¡er containing 1.25 M
NaCl, 20 mM CaCl2, and 20 mM imidazole. Then
the column was washed with elution bu¡er contain-
ing 20 mM imidazole^HCl, pH 7.8, 1.25 M NaCl,
and 2 mM EDTA. Liposomes were incubated with
serum at 37‡C for 10 min before starting the uptake
experiment.
2.5. Harvesting and culture of macrophages
Resident macrophages were collected from the
peritoneal cavity of male ICR mice weighing 20^25
g using balanced salt solution A. Washed cells were
suspended in RPMI 1640 supplemented with 10%
heat-inactivated fetal bovine serum (FBS, Flow Lab-
oratories, Irvine, UK), penicillin G (100 U/ml), and
streptomycin (100 Wg/ml) and then plated on 12-well
culture plates (Falcon, Becton Dickinson, Lincoln
Park, NJ, USA) at a density of 1U106 cells/cm2.
After incubation for 2 h at 37‡C in 5% CO2^95%
air, adherent macrophages were washed with culture
medium and then cultured under the same condi-
tions.
2.6. Cellular uptake study
Uptake studies were carried out after 48 h cultiva-
tion. Cells were washed twice with 1 ml pH 7.4
Hanks’ balanced salt solution (HBSS). The lipo-
somes were preincubated at 37‡C for 10 min with
bu¡er, MBP, serum, or MBP-depleted serum before
cellular uptake studies. The opsonized liposomes
were added to the cells and incubated at 37‡C for
the uptake experiments or incubated at 4‡C for the
binding experiments. At the end of the incubation
period, the medium was removed and the cells were
washed ¢ve times with cold HBSS. The cells were
solubilized with 0.5 ml 1 N NaOH solution overnight
and then neutralized with 0.1 ml 5 N HCl solution.
The radioactivity of [3H]CHE was measured in a
scintillation counter (LSA-500, Beckman, Tokyo,
Japan) after addition of 5.0 ml Clear-Sol I solu-
tion. The protein content was also measured by the
Bradford method using BSA as a standard [19].
2.7. Isolation of mannose binding proteins from rabbit
serum and 111In or FITC labeling
Serum MBP was isolated from normal rabbit se-
rum (Japan Bio-supply) using an a⁄nity column of
Sepharose 4B^mannan, as described previously [20].
Brie£y, frozen rabbit serum was thawed and diluted
with an equal volume of a bu¡er consisting of 40
mM imidazole^HCl, pH 7.8, 40 mM CaCl2W2H2O,
and 2.5 M NaCl. The mixture was applied to the
Sepharose 4B^mannan column equilibrated with
loading bu¡er (20 mM imidazole^HCl, pH 7.8, 20
mM CaCl2W2H2O, and 1.25 M NaCl) and the bound
protein was eluted with an elution bu¡er (20 mM
imidazole^HCl, pH 7.8, 1.25 M NaCl, and 2 mM
EDTA). The eluate was applied to the second and
third smaller a⁄nity columns of Sepharose 4B^man-
Table 1
Lipid composition and mean particle size of the tested liposomes
Lipid composition (molar ratio) Particle size (nm)a
DSPC/Chol (60:40) (Bare-liposomes) 89.4 þ 5.7
DSPC/Chol/Man-C4-Chol (60:35:5) (Man-liposomes) 94.5 þ 10.9
aThe mean particle sizes of the liposomes were measured using a laser light scattering particle size analyzer. Results are expressed as
the mean þ S.D. of three experiments.
BBAMEM 78049 1-3-01 Cyaan Magenta Geel Zwart
P. Opanasopit et al. / Biochimica et Biophysica Acta 1511 (2001) 134^145136
nan. The ¢nal column was washed with loading bu¡-
er and eluted with more loading bu¡er containing
100 mM mannose. All the procedures were carried
out at 4‡C.
The isolated protein was subjected to SDS^PAGE
(10% w/v acrylamide) under reducing and non-reduc-
ing conditions by the method of Laemmli [21]. Mo-
lecular weights were estimated by comparison with
Rainbow marker proteins (Amersham Life Sciences).
MBP was radiolabeled with 111In using the bifunc-
tional chelating agent diethylenetriaminepentaacetic
acid (DTPA) anhydride (Dojindo Labs, Kumamoto,
Japan) by the method of Hnatowich et al. [22].
Brie£y, 10 Wl DTPA anhydride in dimethyl sulfoxide
was added to MBP solution. The mixture was stirred
for 30 min at room temperature, puri¢ed by gel ¢l-
tration chromatography using a PD-10 column
(Pharmacia, Uppsala, Sweden), and eluted with 50
mM HEPES bu¡er (pH 7.8) containing 600 mM
NaCl to remove the unreacted DTPA. The fractions
containing protein derivatives were collected and
111InCl3 solution was added to the DTPA-coupled
MBP. After 30 min, the mixture was puri¢ed by
passing it through a PD-10 column and eluting
with 50 mM HEPES bu¡er (pH 7.8) containing
600 mM NaCl. The fractions containing 111In-MBP
were collected and the protein concentration was de-
termined by the Bradford method using BSA as a
standard [19].
For the confocal microscopic study, MBP was la-
beled with £uorescein isothiocyanate (FITC) as de-
scribed previously [23]. 200 Wg MBP was incubated
with 500 Wg FITC in 50 mM borate bu¡er (pH 9.5)
containing 200 mM NaCl, 20 mM CaCl2, and 100
mM mannose for 18 h at 4‡C. The fractions contain-
ing FITC-MBP were collected from a PD-10 column
and puri¢ed by dialysis with water at 4‡C overnight.
2.8. Binding of 111In-MBP to liposomes
The binding of 111In-MBP to liposomes was tested
by the sedimentation method [24]. The liposomes
(500 Wg) and the 111In-MBP (1 Wg) in 20 mM Tris
bu¡er (pH 7.4) containing 0.15 M NaCl, 5 mM
CaCl2, and 20 mg/ml BSA were separately centri-
fuged at 10 000Ug for 10 min. In the inhibition ex-
periment, 10 mM EDTA or 100 mM mannose was
added in Tris bu¡er. Each liposome pellet was then
suspended in 250 Wl of the supernatant from the
111In-MBP solution. The liposome^protein mixture
was incubated for 1 h at room temperature, placed
on ice, and incubated for 15 min. The mixture was
centrifuged at 10 000Ug for 10 min at 4‡C. The
supernatant was stored and the precipitate was
washed once with 250 Wl ice-cold Tris bu¡er. After
centrifuging, the supernatants were combined. The
amount of 111In-MBP bound to the liposomes was
estimated by counting the radioactivity in a well-type
NaI scintillation counter (ARC-500, Aloka Co.,
Tokyo, Japan).
2.9. Confocal microscopy
For the confocal microscopy study, resident mac-
rophages were cultured at a density of 1U105 cells/
well on a glass-bottom 12-well plate and incubated at
4‡C or 37‡C with PE-rhodamine liposomes, with or
without preincubation with FITC-MBP. After ap-
propriate time intervals, the cells were washed ¢ve
times with ice-cold HBSS and then ¢xed with 4%
paraformaldehyde and 0.01% glutaraldehyde in
PBS(+), and stored overnight at 4‡C. The cells
were mounted in 2.5% DABCO, 90% glycerol,
and PBS(+). The samples were examined by con-
focal laser microscope (ACAS 570 interactive laser
cytometer, Meridian Instruments, Okemos, MI,
USA).
2.10. In vivo distribution of 111In-MBP
111In-MBP (2 Wg), with or without preincubation
with Bare-liposomes or Man-liposomes (500 Wg), was
injected intravenously into a male ddY mouse (25^28
g) via the lateral tail vein. At predetermined time
periods (1, 3, 5, 10, 30, and 60 min) after injection,
blood was collected from the vena cava under ether
anesthesia. The mouse was then sacri¢ced and its
liver, spleen, kidney, and muscle were removed,
rinsed with saline, weighed and their radioactivity
assayed in a well-type NaI scintillation counter
(ARC-500, Aloka Co., Japan).
2.11. Calculation of pharmacokinetic parameters
The distribution data of 111In-MBP were analyzed
in terms of the organ uptake clearance (CLorg) [25].
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After injection of 111In-labeled compound, the
change in the amount of radioactivity in a tissue
with time can be described as
dX i
dt
 CLorgCp3Kefflux;iX i 1
where Xi (normalized to % of the dose) represents
the amount of radioactivity in tissue i after the ad-
ministration of the 111In-labeled compound; Cp (%
of dose/ml) is the concentration of radioactivity in
the plasma; CLorg (ml/h) represents the apparent tis-
sue uptake clearance from the plasma to tissue i ; and
Kefflux;i (h31) represents an e¥ux rate constant from
tissue i. Since little e¥ux of 111In radioactivity from
tissues was observed within the overall experimental
period of 1 h, the e¥ux process can be ignored and
Eq. 1 is simpli¢ed to
dX i
dt
 CLorgCp 2
When Eq. 2 is integrated from time 0 to t, CLorg can
be expressed as
CLorg  X i;tZ t
0
Cpdt
 X i;t
AUCt
3
where AUCt (% of dose h/ml) represents the area
under the plasma concentration^time curve from
time 0 to t, calculated by ¢tting a monoexponential
equation to the plasma concentration^time data of
the 111In radioactivity^time pro¢le using the non-lin-
ear least-squares program MULTI [26]. Therefore,
CLorg can be easily calculated from Eq. 3 at several
time points after administration. The total body
clearance (CLtotal) can be calculated by dividing the
dose by the AUC up to in¢nity.
Fig. 2. The uptake of [3H]Bare-liposomes and [3H]Man-lipo-
somes (50 nmol/ml) with (black bars) and without Man46-BSA
(2 mg/ml) (hatched bars) for 2 h by cultured resident peritoneal
macrophages. Results are expressed as the mean þ S.D. (n = 3).
#P6 0.001; N.S., not signi¢cant.
Fig. 1. (A) Dose-dependent cellular uptake of [3H]Bare-liposomes (b) and [3H]Man-liposomes (F). The cells were incubated with vari-
ous concentrations of liposomes at 37‡C for 2 h. (B) The uptake time courses of [3H]Bare-liposomes (50 nmol/ml) at 37‡C (b) or 4‡C
(a) and [3H]Man-liposomes (50 nmol/ml) at 37‡C (F) or 4‡C (E) for 30 min, 1 h, and 2 h by cultured resident peritoneal macro-
phages. Results are expressed the mean þ S.D. (n = 3).
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3. Results
3.1. Uptake by cultured macrophages
Fig. 1A shows the dose-dependent in vitro uptake
of 3H-labeled liposomes by cultured mouse resident
peritoneal macrophages at 37‡C. Uptake of Man-
liposomes at 2 h was approximately eight-fold great-
er than that of Bare-liposomes. The cellular uptake
increased with time at both 37‡C and 4‡C (Fig. 1B)
but the cellular uptake of Bare-liposomes was mark-
edly lower than that of Man-liposomes at 37‡C.
3.2. Uptake inhibition experiment
Uptake experiments were carried out, with or
without an excess amount of Man-BSA. Fig. 2 shows
a signi¢cant inhibitory e¡ect of Man-BSA on Man-
liposome uptake (P6 0.001) by macrophages, where-
as no signi¢cant uptake was observed for Bare-lipo-
somes.
3.3. Uptake of [3H]liposomes preincubated with
serum-type MBP
Under reducing conditions, a single band (about
30 kDa) could be detected on the SDS^PAGE of the
protein(s) puri¢ed from rabbit serum or mouse se-
rum using an a⁄nity column (Fig. 3). On the other
hand, several high molecular weight bands were seen
under non-reducing conditions. These results agreed
with those of previous papers [20,27], indicating that
both proteins puri¢ed from rabbit and mouse serum
Table 2
Binding of 111In-MBP to liposomes measured by the sedimenta-
tion method and the inhibitory e¡ect of 10 mM EDTA and
100 mM mannose on the binding of 111In-MBP to liposomes
Compound Bare-liposomes
(% of dose)
Man-liposomes
(% of dose)
Control 16.68 þ 1.85 31.27 þ 1.07
10 mM EDTA 6.20 þ 0.63 17.37 þ 3.33
100 mM mannose 14.82 þ 2.36 12.49 þ 0.92
The results are expressed as the mean þ S.D. of three experi-
ments.
Fig. 4. E¡ect of MBP on the uptake of [3H]Bare-liposomes and
[3H]Man-liposomes by cultured resident peritoneal macro-
phages. Both types of liposomes (50 nmol/ml) were incubated
with (black bars) and without MBP (1 Wg/ml) (hatched bars) at
37‡C for 10 min before starting the cellular uptake experiment
at 37‡C for 2 h. Results are expressed as the mean þ S.D.
(n = 3). #P6 0.001; N.S., not signi¢cant
Fig. 3. SDS^PAGE of isolated mannose binding protein. Puri-
¢ed binding protein was subjected to 10% polyacrylamide gel
electrophoresis under reducing conditions (L-mercaptoethanol).
Molecular weight marker in lane 1, mannose binding protein
isolated from rabbit serum in lane 2, and mouse serum in lane
3. The binding protein band has an apparent molecular weight
of approx. 30 kDa.
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are serum-type MBP. To clarify the e¡ect of MBP,
[3H]liposomes were preincubated with MBP at 37‡C
for 10 min before the uptake experiment. It is ob-
vious from Fig. 4 that MBP markedly enhanced the
uptake of both [3H]Bare-liposomes and [3H]Man-
liposomes, but this e¡ect was greater for [3H]Man-
liposomes.
3.4. Binding of 111In-MBP to liposomes
The binding of 111In-MBP to liposomes was deter-
mined by the sedimentation method and the results
are summarized in Table 2. This shows that an ap-
proximately two-fold greater amount of 111In-MBP
was co-sedimented with Man-liposomes than Bare-
liposomes and this binding was also inhibited by
10 mM EDTA or 100 mM mannose.
3.5. E¡ect of serum on the uptake
The e¡ects of serum or its components on in vitro
uptake were investigated. The results in Fig. 5 show
Fig. 7. Confocal microscopy images of binding and internalization of Man-liposomes by mouse peritoneal macrophages. Macrophages
were incubated with PE-rhodamine Man-liposomes for 2 h at 4‡C (A), or at 37‡C (B). The images are typical of at least three inde-
pendent experiments.
Fig. 6. E¡ect of serum and MBP-depleted serum on the cellular
uptake of [3H]Bare-liposomes (hatched bars) and Man-lipo-
somes (black bars) by cultured resident peritoneal macrophages.
Liposomes (50 nmol/ml) were incubated at 37‡C for 10 min
with 10% normal serum or MBP-depleted serum before starting
the cellular uptake experiment at 37‡C for 2 h. Control experi-
ments were carried out without serum. Results are expressed as
the mean þ S.D. (n = 3). #P6 0.001; N.S., not signi¢cant.
Fig. 5. E¡ect of preincubation with various concentrations of
serum on the cellular uptake of [3H]Bare-liposomes (a) and
[3H]Man-liposomes (F) by cultured resident peritoneal macro-
phages. Liposomes (50 nmol/ml) were incubated with various
concentrations of normal serum at 37‡C for 10 min before
starting the cellular uptake experiment at 37‡C for 2 h. Results
are expressed as the mean þ S.D. (n = 3).
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that the uptake of Man-liposomes incubated with
serum signi¢cantly decreased on increasing the con-
centration of serum. The uptake of liposomes by
macrophages in the presence of serum, with or with-
out MBP, is compared in Fig. 6. The uptake of Bare-
liposomes by macrophages was una¡ected by both
serum samples. On the other hand, serum drastically
suppressed the uptake of Man-liposomes by macro-
phages, but the uptake was still greater than that for
Bare-liposomes. Man-liposomes preincubated with
MBP-depleted serum showed a signi¢cantly lower
uptake than with normal serum indicating involve-
ment of MBP in the uptake of Man-liposomes by
macrophages.
Fig. 8. Confocal microscopy of FITC-MBP preincubated with PE-rhodamine Bare-liposomes and PE-rhodamine Man-liposomes in
the culture of mouse peritoneal macrophages. Macrophages incubated with FITC-MBP at 37‡C for 2 h are shown by the green color
of FITC (A). Macrophages incubated with a mixture of FITC-MBP and PE-rhodamine Bare-liposomes at 37‡C for 2 h are displayed
in three panels with green (FITC) (B), red (PE-rhodamine) (C), and yellow (depicting colocalization) (D) signals. Macrophages incu-
bated with a mixture of FITC-MBP and PE-rhodamine Man-liposomes at 37‡C for 2 h are displayed in three panels with green
(FITC) (E), red (PE-rhodamine) (F), and yellow (depicting colocalization) (G) signals. Typical images of the distribution pattern from
at least three independent experiments are shown.
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3.6. Confocal microscopy
The results of confocal microscopy are shown in
Fig. 7 and these suggest close agreement with those
obtained in the in vitro uptake experiment. Confocal
microscopy images revealed time-dependent binding
at 4‡C (Fig. 7A) and internalization at 37‡C (Fig.
7B) of Man-liposomes by macrophages. In addition,
about 50% of the bound Man-liposomes were inter-
nalized in 30 min (data not shown). Bare-liposomes
showed a similar pattern of binding and internaliza-
tion, but the number of cells exhibiting binding and
internalization was less than 10% of the total cells,
whereas the ¢gure was more than 90% for Man-lipo-
somes.
To clarify the e¡ect of MBP on the uptake of
Man-liposomes, colocalization images were examined
(Fig. 8). The photographs show that FITC-MBP
(Fig. 8A) was internalized into macrophages, but
the £uorescence signal was rather weaker than that
of the complex with PE-rhodamine Bare-liposomes
(Fig. 8B) and PE-rhodamine Man-liposomes (Fig.
8E). FITC-MBP preincubated with PE-rhodamine
Bare-liposomes (Fig. 8D) and with PE-rhodamine
Man-liposomes(Fig. 8G) is internalized into macro-
phages. As shown by the yellow signal depicting co-
localization, FITC-MBP exhibited increased colocal-
ization with PE-rhodamine Man-liposomes and PE-
rhodamine Bare-liposomes. The number of cells ex-
hibiting colocalization of PE-rhodamine Bare-lipo-
somes with FITC-MBP was less than 10% of the
total cells, whereas more than 90% of cells showed
colocalization for Man-liposomes.
3.7. In vivo distribution of 111In-MBP
Fig. 9 shows the plasma concentration and liver
accumulation time courses of 111In-MBP after intra-
venous injection in mice, with or without preincuba-
tion with Bare-liposomes and Man-liposomes.
Although 111In-MBP was mainly recovered in the
liver in all cases, the hepatic uptake of 111In-MBP
preincubated with Man-liposomes was the greatest.
Table 3 summarizes the AUC, CLtotal, hepatic uptake
clearance (CLliver), and tissue uptake rate index of
111In-MBP after intravenous injection. The CLliver
made a major contribution to the CLtotal, suggesting
that the liver is the main organ for 111In-MBP
uptake. The results con¢rmed that binding to
Man-liposomes enhanced the hepatic uptake of
111In-MBP.
4. Discussion
Cell-speci¢c targeting systems using carbohydrate
Table 3
AUC, clearances, and tissue uptake rate index of 111In-MBP, 111In-MBP preincubated with Bare-liposomes, and 111In-MBP preincu-
bated with Man-liposomes after intravenous injection in mice
Compound AUC (% of dose h/ml) Clearance (ml/h) Tissue uptake rate index (ml/h/g)
Cltotal Clliver Liver Kidney Spleen Muscle
In-MBP 16.56 6.03 2.15 1.3 1.4 0.9 0.001
In-MBP+Bare-liposomes 16.43 5.73 2.04 1.2 1.6 0.8 0.003
In-MBP+Man-liposomes 15.34 6.52 3.23 2.3 2.1 2.4 0.003
Fig. 9. Time courses of the plasma concentration (upper) and
liver accumulation (lower) of 111In-MBP preincubated with
Bare-liposomes (left : E) and Man-liposomes (right: O) or with-
out preincubation (b) after intravenous injection into mice. Re-
sults are expressed as the mean þ S.D. of three mice.
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recognition mechanisms have attracted great interest
as far as drug and gene delivery are concerned, and
we have reported developments of various polymeric
or particulate carriers in this context [28^30]. How-
ever, in order to achieve highly speci¢c cellular tar-
geting via receptor-mediated endocytosis, we need to
pay great attention to interactions of carriers with
biological components such as serum binding pro-
tein. For example, Kawasaki et al. [31] reported
that MBP, mannose-speci¢c lectin, circulates in se-
rum, binds to pathogens having mannose units on
their surface, and functions directly as an opsonin
recognized by the collectin receptor on macrophages
[32,33] and complement activation [34,35]. In our
series of investigations, we have described the e¡ect
of speci¢c binding to MBP on the targeting potential
of mannosylated polymer carriers in mice. Dose-de-
pendent reiteration of cell-speci¢c hepatic uptake due
to complex formation was con¢rmed by a pharma-
cokinetic analysis (submitted): serum MBP retarded
hepatic uptake of mannosylated polymer at lower
doses of 0.05 and 0.1 mg/kg. At doses between 0.1
and 1 mg/kg, the binding to MBP was saturated and
excess ligands existing in a free form were recognized
by hepatic mannose receptors resulting in rapid he-
patic uptake. At doses over 1 mg/kg, the mannose
receptors were also saturated with ligands and the
hepatic uptake was retarded again. A similar phe-
nomenon would be suspected for particulate carriers
such as mannosylated liposomes, but little informa-
tion has been obtained about the e¡ects of MBP on
the in vivo behavior of Man-liposomes. Therefore, in
this investigation, the roles of MBP and mannose
receptor in the uptake of Man-liposomes by macro-
phages were studied in detail.
In general, liposome composed of DSPC and Chol
and small in size, such as 6 100 nm, are known to
have a long half-life in the blood circulation due to
their ability to avoid reticuloendothelial systems
(RES) trapping [36], failure to undergo complement
activation [37], and a lower susceptibility to destruc-
tion by serum components [38]. Therefore, in our
approach, we chose DSPC/Chol liposomes as Bare-
liposomes for modi¢cation with Man-C4-Chol to ob-
tain mannosylated targeting liposomes. The in vitro
uptake experiment demonstrated the rapid attach-
ment and internalization of Man-liposomes by peri-
toneal macrophages (Fig. 1) and similar results were
obtained by confocal microscopy observations (Fig.
7). Furthermore, the uptake was dose-dependent
(Fig. 1) and inhibited by Man-BSA (Fig. 2). These
results suggest that the mannose residues on the sur-
face of Man-liposomes present a conformational mo-
bility which allows interaction with the mannose re-
ceptors of the macrophages under serum-free
conditions. However, this may not be the case in
vivo since administered liposomes would be exposed
to serum components including MBP.
When mannosylated ligands interact with serum,
their biodistribution becomes more complicated.
The serum components that can recognize the man-
nose moiety or simply be adsorbed on Man-lipo-
somes may accelerate (opsonins) or suppress (disop-
sonins) the mannose-speci¢c uptake of Man-
liposomes, respectively. Thus, the apparent hepatic
disposition feather would be observed in the balance
of the acceleration and suppression. In Fig. 4 puri¢ed
MBP enhanced the uptake of both Bare-liposomes
and Man-liposomes but the increase was greater for
Man-liposomes. These results are in good agreement
with the results of confocal microscopy in that the
number of cells exhibiting colocalization of FITC-
MBP and PE-rhodamine-labeled liposomes for
Bare-liposomes was less than 10% of total cells,
whereas it was more than 90% for Man-liposomes.
The enhancement of the uptake of Bare-liposomes by
MBP might be provoked by the non-speci¢c adsorp-
tion on the liposomal surface or the speci¢c binding
of MBP to phospholipids since binding of MBP to
phospholipids and liposomes in addition to mannose
moieties was also reported in previous studies [39]. In
vivo experiments also demonstrated that only Man-
liposomes enhanced the hepatic uptake of 111In-MBP
(Fig. 9) suggesting e¡ective uptake of the complex of
MBP and Man-liposomes by macrophages. More-
over, [3H]CHE-labeled Man-liposomes complexed
with 111In-MBP showed greater uptake than
[3H]liposomes administered alone (data not show).
Serum albumin, the major serum protein, has been
reported to reduce the hepatic uptake of polystyrene
colloidal particles by coating the hydrophobic sur-
face of particles [40]. In this study, the uptake experi-
ments demonstrated that serum components present
on the surface of Man-liposomes suppressed its cel-
lular uptake (Fig. 5), probably due to disruption of
the speci¢c interaction between the mannose moiety
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and the receptor on the macrophages. A similar ef-
fect was observed for serum heated at 56‡C for 30
min (decomplemented serum) (data not shown).
These results suggest that heat-stable serum compo-
nents such as albumin might coat the liposomal sur-
face and inhibit recognition. This result seems to be
inconsistent with the previous report of Matsuo et al.
[41] who demonstrated stimulatory and inhibitory
e¡ects of serum and heated serum, respectively, on
the uptake of multilamellar vesicles with cetylmanno-
side in the in situ hepatic uptake experiments. They
suggested the involvement of complement but not the
mannose receptor. This discrepancy could be due to
di¡erences in the size and types of the mannose moi-
eties as well as lipid composition of the liposomes.
On the other hand, MBP-depleted serum showed a
signi¢cantly higher uptake inhibition for Man-lipo-
somes than normal serum, suggesting involvement of
MBP in uptake by macrophages (Fig. 6). Further
study is necessary to clarify the detailed role of serum
components in the suppression of cellular uptake of
liposomes.
In a previous study, we have found that the solu-
ble mannosylated polymer complexed with MBP
loses its ability to be recognized by macrophages
(submitted). Although the structure, functions, and
manner of binding to simple sugar of MBP have
been extensively studied [13^15], no study has so
far shown the relationship between the characteristics
of the mannosylated ligands and the uptake e⁄-
ciency of its MBP complex. The critical features of
the ligands, such as their size and shape and the
mechanisms of inhibition or stimulation of MBP
on the uptake of mannosylated ligands, remain to
be elucidated. It has been reported that MBP can
be recognized by collectin receptors expressed on
macrophages, monocytes, and neutrophils [42] and
the collagen-like N-terminal region of MBP is re-
sponsible for this interaction. It has been hypothe-
sized that the collagenous region of the MBP motif is
normally masked by the MBP-associated serine pro-
tease (MASP). However, following complement acti-
vation, MASP is removed to reveal the collectin re-
ceptor binding sites. Alternatively, binding of
mannosylated ligands to the carbohydrate recogni-
tion domain region might result in a conformational
change in the collagenous region with exposure of a
previously hidden site, leading to binding and inter-
nalization of the MBP/mannosylated ligand complex
into the macrophages by collectin receptors [43]. In
the case of soluble mannosylated polymers, MBP
hides mannose moieties while retaining its soluble
form. Although the interaction between MBP and
mannosylated polymeric ligands leads to tight and
speci¢c binding through multivalent interaction, it
could not produce a conformational change in the
collagenous region in MBP. These di¡erences could
be explained in terms of the size and shape of the
ligands, rather than the clustering e¡ect of the multi-
valent interaction. Thus, the characteristics of man-
nosylated ligands are crucial as far as exposure of the
binding sites of the collagenous region is concerned.
Native and recombinant MBP have been shown to
bind to virulent S. montevideo expressing a mannose-
rich O-polysaccharide which results in attachment,
uptake, and killing of the coated bacteria by phago-
cytes, providing the ¢rst evidence that MBP can act
as an opsonin [44]. Thus, it has been presumed that
this direct opsonin activity is mediated by a collectin-
speci¢c receptor expressed on phagocytic cell surfa-
ces, although the physiological importance of the
MBP interaction with the collectin receptor(s) re-
mains unclear due to the absence of data on receptor
kinetics and expression. On the other hand, Tenner
et al. [45] recently showed that MBP does not asso-
ciate or bind to the target being ingested. Rather,
cellular interaction with MBP alone induces, as yet
unknown, intracellular responses, possibly binding of
a target to independent recognition receptors like
FcR or CR1. The exact mechanism involved needs
further investigation.
In summary, the novel mannosylated liposomes
developed for liver non-parenchymal cell selective
targeting were con¢rmed to be recognized by the
mannose receptors of macrophages with a high de-
gree of speci¢city. In addition to the mannose recep-
tor, serum MBP speci¢cally associates at the surface
of Man-liposomes and enhances its binding and in-
ternalization by macrophages. On the other hand,
some components in serum simply interfere with
the recognition by coating the surface of liposomes.
The characterization of these interactions between
Man-liposomes and the macrophage receptors or
MBP would not only provide fundamental informa-
tion for the rational design of cell-speci¢c carriers,
but also suggest a role of these interactions in infec-
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tion and other pathological conditions involving
macrophages.
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